A stalwart of the British political scene, Larry the Cat has ruled the roost in Downing Street for a decade, serving three prime ministers and becoming a legend in his own naptime.
The tabby-and-white cat arrived at 10 Downing Street on Feb. 15, 2011, at the age of four.
He was adopted from London’s Battersea Dogs & Cats Home, an animal shelter, and was chosen for his mousing skills, according to his biography on the Downing Street Web site.
He received the title of Chief Mouser the first inhabitant of the prime minister’s famous residence and office to do so.
However, while he
A new type of drug that helps target chemotherapy directly to cancer cells significantly increases survival of patients with the most common form of bladder cancer, new research suggests.
The risk of death was 30% lower with the new drug than with chemotherapy, with an average survival of approximately 13 months for the new drug, according to the new study.
Urothelial cancer is the most common type of bladder cancer and accounts for around 90% of cases.
It can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra.
Share this article
Share this article
TOKYO and BOTHELL, Wash., Feb. 12, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) and Seagen Inc. (Nasdaq: SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV
® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. At the time of pre-specified interim analysis, patients who received PADCEV in the trial lived a median of 3.9 months longer than those who received chemotherapy. Median overall survival was 12.9 vs. 9.0 months, respectively (HR=0.70 [95 percent Confidence Interval (CI): 0.56-0.89], p=0.001). For patients in the PADCEV arm of the trial, maculopapular rash, fatigue and decreased neutrophil count were the most frequent Grade 3 or greater treatment-related adverse events (TRAEs) occurring in more tha
E-Mail
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust.
The results are published in the
New England Journal of Medicine and were presented at the 2021 American Society of Clinical Oncology s Genitourinary Cancers Symposium.
Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra. Globally, approximately 549,000 new cases of bladder cancer and 200,000 deaths are reported annually.
E-Mail
A study by researchers at Queen Mary University in London has investigated how women who are at high risk of ovarian cancer make choices about possible preventive surgery.
Women who have BRCA1 and BRCA2 genetic mutations have a 17-44% lifetime risk of ovarian cancer. Scientists now believe that most ovarian cancers begin in the fallopian tubes, and so women at high risk can choose to undergo surgery to remove both their fallopian tubes and ovaries to reduce their risk. For those who have not yet reached menopause, there are difficult decisions around the order and timing of surgeries, as removing the ovaries will induce menopause.